

On: 08 June 2015, At: 01:41

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Oncoimmunology

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/koni20>

Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings

Bilgi Gungor^a, Fuat Cem Yagci^b, Ihsan Gursel^b & Mayda Gursel^a

^a Department of Biological Sciences; Middle East Technical University; Ankara, Turkey

^b Department of Molecular Biology and Genetics Bilkent University; Ankara, Turkey

Published online: 29 Oct 2014.



[Click for updates](#)

To cite this article: Bilgi Gungor, Fuat Cem Yagci, Ihsan Gursel & Mayda Gursel (2014) Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings, *Oncoimmunology*, 3:7, e950166, DOI: [10.4161/21624011.2014.950166](https://doi.org/10.4161/21624011.2014.950166)

To link to this article: <http://dx.doi.org/10.4161/21624011.2014.950166>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Versions of published Taylor & Francis and Routledge Open articles and Taylor & Francis and Routledge Open Select articles posted to institutional or subject repositories or any other third-party website are without warranty from Taylor & Francis of any kind, either expressed or implied, including, but not limited to, warranties of merchantability, fitness for a particular purpose, or non-infringement. Any opinions and views expressed in this article are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

It is essential that you check the license status of any given Open and Open Select article to confirm conditions of access and use.

Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings

Bilgi Gungor¹, Fuat Cem Yagci², Ihsan Gursel², and Mayda Gursel^{1,*}

¹Department of Biological Sciences; Middle East Technical University; Ankara, Turkey; ²Department of Molecular Biology and Genetics Bilkent University; Ankara, Turkey

Keywords: CpG ODN, Type I interferon, vaccine adjuvant

Type I interferon inducers may potentially be engineered to function as antiviral and anticancer agents, or alternatively, vaccine adjuvants, all of which may have clinical applications. We recently described a simple strategy to convert a Toll-like receptor 9 (TLR9) agonist devoid of interferon α (IFN α) stimulating activity into a robust Type I interferon inducer with potent vaccine adjuvant activity.

Single stranded synthetic oligodeoxynucleotides containing unmethylated cytosine-phosphate-guanine dinucleotide motifs (CpG ODN) mimic the immune stimulatory effect of bacterial DNA and constitute a family of immunotherapeutics that stimulate the cells of the innate immune system expressing the endosomal pattern recognition receptor Toll-like receptor 9 (TLR9).¹ CpG ODNs are classified into 4 distinct subtypes on the basis of their sequence, the nature of the ODN backbone, the presence of secondary structures and differential immune activation patterns observed among stimulated human peripheral blood mononuclear cells (PBMCs).² Of these, K-class CpG ODNs (referred to as CpG-B by other groups) have linear phosphorothioate (PS) backbones, express multiple TCGTT and/or TCGTA motifs and strongly activate B cells.³ K-ODNs promote the survival, activation and maturation of plasmacytoid dendritic cells (pDC) but induce no IFN α secretion.³⁻⁵ To date, the majority of clinical trials have been based on this ODN class.⁶ The D-class ODN (referred to as CpG-A by other groups), contain a single palindromic phosphodiester purine/pyrimidine/CG/purine/pyrimidine motif linked to a poly(G) tail at their 3' end.³ The palindromic

sequence and the poly(G) tail enable D-type ODNs to form Hoogsteen base paired G-quadruplexes and higher order structures that can be globular (~50 nm size), linear (~100 nm size) or 2 forked.⁷ Formation of such multimeric structures permits D- but not K-type ODN to bind to the transmembrane form of the chemokine and scavenger receptor chemokine (C-X-C) ligand 16 (CXCL16) expressed on the surface of pDCs.⁸ This interaction directs the ODN into early endosomes, triggering a TLR9-MyD88-IRF7-mediated signaling pathway, leading to robust IFN α production.⁹ The D-ODN-induced vigorous IFN α response may have potential benefits in the prevention/treatment of viral infections and/or malignancies. However, formation of spontaneous, uncontrollable higher order structures with D-class ODN complicates their pharmaceutical manufacturing process, precluding them from human clinical trials. The remaining 2 CpG ODN classes are either weak Type I interferon-inducers (C-class), or are dependent upon "high-salt buffers" to form IFN α stimulating concatameric structures (P-class), making them less potent or unpredictable for use as alternates of D-ODN.

Recently, we have demonstrated a simple strategy to convert a conventional

K-type ODN into a potent Type I interferon inducer by multimerizing the ODN into ordered nanostructures through complexation with a cationic peptide.¹⁰ In general, polycation induced condensation of ODN generates aggregates with a heterogeneous distribution. To avoid such an outcome, we hypothesized that a very short and hence non-flexible ODN would condense into well-defined spheres when mixed with a short peptide of high positive charge density. Our results demonstrated that among the cationic peptides tested, the 11-mer, +8 charged HIV-derived peptide Tat₍₄₇₋₅₇₎ condensed a 12-mer but not a more flexible 20-mer ODN into rigid individual building blocks that subsequently re-organized to forge stable, monodispersed nanorings (Fig. 1A).¹⁰ The nanorings generated a vigorous pDC-dependent IFN α response and an indirect monocyte-dependent CXCL10/IP-10 response in human blood that reciprocated D-ODN activity.¹⁰ Since differences in subcellular distribution of ODN directly affect the type of response (i.e, the IFN α eliciting capacity), we further analyzed the endosomal localization patterns. Results showed that condensation with Tat peptide redirected K-ODN to early endosomes (Fig. 1A). This subcellular


© Bilgi Gungor, Fuat Cem Yagci, Ihsan Gursel, and Mayda Gursel

*Correspondence to: Mayda Gursel; Email: mgursel@metu.edu.tr

Submitted: 06/24/2014; Accepted: 07/02/2014

<http://dx.doi.org/10.4161/21624011.2014.950166>

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.



vaccine.¹⁰ The response was characterized by an isotype switching toward IgG2a, suggestive of T helper type 1 (Th1) support (Fig. 1B). In a different setting, C57BL/6 mice bearing ovalbumin (OVA)-expressing EG.7 thymoma tumors were therapeutically vaccinated with the model tumor antigen OVA plus the adjuvants. The nanoring adjuvanted group displayed significant reduction in tumor size and progression.¹⁰ Type I interferons can directly trigger clonal expansion and memory formation in CD8+ T cells. Consistent with this view, nanorings triggered expansion in the CD8+ T cell pool and elicited superior tumor-specific immunity (Fig. 1B) characterized by increased OVA-specific interferon γ (IFN γ) production. Next, to assess whether the nanorings required the presence of pDCs for their activity, we depleted this cell population *in vivo* and examined the induction of antibody response to the model antigen OVA. In pDC undepleted mice, both the nanoring and the D-ODN adjuvanted groups generated approximately 80-fold higher OVA-specific IgG2a titers when compared to antigen alone. This activity was severely impaired in mice depleted of pDCs, suggesting that pDC activation and ensuing Type I IFN production is critical for the adjuvanticity.¹⁰

Clinical use of Type I interferon-inducing TLR agonists such as the TLR7/8 agonist R837 is currently limited to the topical treatment of genital warts, basal cell carcinoma, and bladder cancer. Systemic administration of imidazoquinolines incite a TLR7-independent immunotoxicity by antagonizing the adenosine receptors. Therefore, the development of other

distribution pattern is consistent with efficient IFN α production.

The nanorings were also found to be more effective than K-ODN in

stimulating long-term antigen-specific antibody production *in vivo* when administered with a suboptimal dose of the inactivated foot and mouse disease

administration of imidazoquinolines incite a TLR7-independent immunotoxicity by antagonizing the adenosine receptors. Therefore, the development of other

TLR-based Type I interferon inducers suitable for systemic use as adjuvants is highly desirable. We believe that our recent findings in regards to the performance of the nanorings *in vivo* are encouraging and may prove to be of value as antiviral or anticancer agents and vaccine adjuvants in the clinic. However, whether the nanorings would withstand testing in non-human primates where the cellular

expression of TLR9 is more restricted than in mice remains to be seen.

government. The authors declare no competing financial interests.

Disclosure of Potential Conflicts of Interest

MG and IG are among the co-inventors of patents concerning the activity of CpG ODN, including their use as vaccine adjuvants. The rights to all such patents have been transferred to the US

Funding

The authors would like to thank the Scientific and Technological Research Council of Turkey (TUBITAK) for their generous funding (111S151).

References

1. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. *Nat Rev Immunol* 2004;4:249-58; PMID:15057783; <http://dx.doi.org/10.1038/nri1329>
2. Hanagata N. Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system. *Int J Nanomedicine* 2012;7:2181-95; PMID:22619554; <http://dx.doi.org/10.2147/IJN.S30197>
3. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral blood cells differentially recognize and respond to two distinct CpG motifs. *J Immunol* 2001;166:2372-7; PMID:11160295; <http://dx.doi.org/10.4049/jimmunol.166.4.2372>
4. Gursel M, Verthelyi D, Gursel I, Ishii KJ, Klinman DM. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. *J Leukoc Biol* 2002;71:813-20; PMID:11994506
5. Gursel M, Verthelyi D, Klinman DM. CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. *Eur J Immunol* 2002;32:2617-22; PMID:12207346; [http://dx.doi.org/10.1002/1521-4141\(200209\)32:9%3c2617::AID-IMMU2617%3e3.0.CO;2-F](http://dx.doi.org/10.1002/1521-4141(200209)32:9%3c2617::AID-IMMU2617%3e3.0.CO;2-F)
6. Krieg AM. CpG still rocks! Update on an accidental drug. *Nucleic Acid Ther* 2012;22:77-89; PMID:22352814; <http://dx.doi.org/10.1089/nat.2012.0340>
7. Kerkmann M, Costa LT, Richter C, Rothenfusser S, Battiany J, Hornung V, Johnson J, Englert S, Ketterer T, Heckl W, et al. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells. *J Biol Chem* 2005;280:8086-93; PMID:15591070; <http://dx.doi.org/10.1074/jbc.M410868200>
8. Gursel M, Gursel I, Mostowski HS, Klinman DM. CXCL16 influences the nature and specificity of CpG-induced immune activation. *J Immunol* 2006;177:1575-80; PMID:16849465; <http://dx.doi.org/10.4049/jimmunol.177.3.1575>
9. Honda K, Ohba Y, Yanai H, Negishi H, Mizutani T, Takaoka A, Taya C, Taniguchi T. Spatiotemporal regulation of MyD88-IRF-7 signalling for robust type-I interferon induction. *Nature* 2005;434:1035-40; PMID:15815647; <http://dx.doi.org/10.1038/nature03547>
10. Gungor B, Yagci FC, Tincer G, Bayyurt B, Alpdundar E, Yildiz S, Ozcan M, Gursel I, Gursel M. CpG ODN nanorings induce IFN α from plasmacytoid dendritic cells and demonstrate potent vaccine adjuvant activity. *Sci Transl Med* 2014;6:235ra61; PMID:24807558; <http://dx.doi.org/10.1126/scitranslmed.3007909>